^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Biliary Tract Cancer |
| Drug: | Acelarin (fosgemcitabine palabenamide) (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
NuCana Receives Fast Track Designation from the U.S. Food and Drug Administration for Acelarin® (NUC-1031) for the Treatment of Biliary Tract Cancer
Published date:
09/29/2021
Excerpt:
NuCana plc (NASDAQ: NCNA) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Acelarin (NUC-1031), currently being evaluated in a Phase III study (NuTide:121) for the first-line treatment of patients with advanced biliary tract cancer.
Trial ID:
